| 肝移植术后FK506个体化应用的研究进展 |
| |
| 引用本文： | 陆英杰,ZHANG Jin-Yan,王兆文,PENG Zhi-Hai.肝移植术后FK506个体化应用的研究进展[J].国际外科学杂志,2008,35(8):528-531. |
| |
| 作者姓名： | 陆英杰 ZHANG Jin-Yan 王兆文 PENG Zhi-Hai |
| |
| 作者单位： | 1. 上海交通大学附属第一人民医院普外科,上海,200080
2. Department of General Surgery, Shanghai First People's Hospital, Shanghai 200080, China |
| |
| 基金项目： | 上海市科学技术委员会科研计划相关项目 |
| |
| 摘 要： | FKS06是肝移植术后常用的免疫抑制剂,存在治疗窗狭窄、个体间和个体内变异性大等特点.对移植患者术后血药浓度的监测是目前临床免疫抑制方案调整的主要依据,但仍缺乏较稳定的预见性和指导性.以遗传多态性为基础的药物基因组学的发展为个体化用药提供了更为合理的发展方向.目前国内外的器官移植领域个体化免疫抑制治疗相关研究多围绕细胞色素代谢酶(P450)、P-糖蛋白(PgP)及核内受体编码基因的多态性展开.
|
| 关 键 词： | 药物基因组学 P-糖蛋白 细胞色素代谢酶 核内受体 |
Individual FKS06 administration in liver transplantation |
| |
| LU Ying-fie,ZHANG Jin-Yan,WANG Zhao-Wen,PENG Zhi-Hai.Individual FKS06 administration in liver transplantation[J].International Journal of Surgery,2008,35(8):528-531. |
| |
| Authors: | LU Ying-fie ZHANG Jin-Yan WANG Zhao-Wen PENG Zhi-Hai |
| |
| Abstract: | Tacrolimus, an immunosuppressant used after liver transplantation, has a narrow therapeutic range and its pharmacokinetic variability complicates its daily dose assessment. Therapeutic drug monitoring after liver transplantation, which is the mainstay to clinical immue suppression adjustment, still has its short- age. The development of pharmacogenomics depends on genetic polymorphism provides more reasonable di- rections to individualized immunosuppressive therapy. At present, the researches of the therapy mainly focus on the genetic polymorphism of coding gene of P450, PgP and nuclear receptor. |
| |
| Keywords: | FK506 |
| 本文献已被 万方数据 等数据库收录！ |
|
